Vaccinex (NASDAQ:VCNX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Friday, Zacks.com reports.

According to Zacks, “Vaccinex, Inc. is a clinical-stage immunotherapy company. It engages in the discovery and development of biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune disorders. The company’s product pipeline consists of VX15, VX5 and VX25 which are in clinical stage. Vaccinex, Inc. is based in Rochester, New York. “

Separately, ValuEngine raised Vaccinex from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st.

NASDAQ:VCNX traded down $0.37 during trading hours on Friday, hitting $5.61. The company’s stock had a trading volume of 570 shares, compared to its average volume of 3,056. The stock has a fifty day simple moving average of $5.17 and a 200-day simple moving average of $5.51. The company has a market capitalization of $86.80 million and a P/E ratio of -1.08. Vaccinex has a twelve month low of $3.32 and a twelve month high of $10.05.

Vaccinex (NASDAQ:VCNX) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.07). The business had revenue of $0.03 million during the quarter. Vaccinex had a negative net margin of 6,349.13% and a negative return on equity of 306.27%. Equities research analysts forecast that Vaccinex will post -2.6 EPS for the current fiscal year.

In other Vaccinex news, major shareholder Catalyst Group Managem General acquired 2,678,571 shares of Vaccinex stock in a transaction that occurred on Monday, July 29th. The shares were acquired at an average cost of $28.00 per share, with a total value of $74,999,988.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Albert Friedberg acquired 1,838,235 shares of Vaccinex stock in a transaction that occurred on Tuesday, July 30th. The stock was acquired at an average cost of $4.08 per share, for a total transaction of $7,499,998.80. The disclosure for this purchase can be found here. Insiders purchased 4,701,682 shares of company stock worth $83,254,186 over the last ninety days. 69.90% of the stock is currently owned by insiders.

A hedge fund recently bought a new stake in Vaccinex stock. Oppenheimer & Co. Inc. purchased a new stake in shares of Vaccinex Inc (NASDAQ:VCNX) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 15,800 shares of the company’s stock, valued at approximately $87,000. Oppenheimer & Co. Inc. owned approximately 0.14% of Vaccinex at the end of the most recent quarter. Hedge funds and other institutional investors own 1.30% of the company’s stock.

Vaccinex Company Profile

Vaccinex, Inc, a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), osteosarcoma, melanoma, and Huntington's disease.

Further Reading: Call Option Volume

Get a free copy of the Zacks research report on Vaccinex (VCNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vaccinex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccinex and related companies with MarketBeat.com's FREE daily email newsletter.